-

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results on February 21

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

Conference Call Details

Date:

 

Wednesday, Feb. 21, 2024

 

Time:

 

8 a.m. ET

 

Webcast:

 

https://www.webcaster4.com/Webcast/Page/2883/49630

 

Participant Event Dial-in:

 

+1 (888) 506-0062 (North America)

+1 (973) 528-0011 (International)

 

Participant Access Code:

 

181271

 

Replay Dial-in:

 

+1 (877) 481-4010 (North America)

+1 (919) 882-2331 (International)

 

Replay Passcode:

 

49630 (replay available until March 6, 2024)

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

© 2024 Bausch + Lomb.

Contacts

Media Contact:
T.J. Crawford
tj.crawford@bausch.com
(908) 705-2851

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Media Contact:
T.J. Crawford
tj.crawford@bausch.com
(908) 705-2851

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

More News From Bausch + Lomb Corporation

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results. “Helping people see better to live better starts with tackling the challenges patients still face every day,” said Bausch + Lomb CEO Brent Saunders. “These results suppor...

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors. At the request of Bausch Health Companies Inc. (“Bausch Health”), which has held a majority ownership position in Bausch + Lomb since its initial public offering in 2022 and currently owns, directly or indirectly through its wholly owned subsidiaries, approximately 87% of the c...

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2026 financial results. “Broad-based revenue growth, leverage in the P&L, margin expansion and conversion to cash flow. These have been themes since we unveiled our three-year plan for growth at Investor Day last November, and in the second quarter progress continued at an accelerated pace...
Back to Newsroom